Verici Dx plc (LON:VRCI – Get Free Report)’s share price traded down 8.2% during mid-day trading on Thursday . The stock traded as low as GBX 4.13 ($0.05) and last traded at GBX 4.13 ($0.05). 802,892 shares were traded during trading, an increase of 147% from the average session volume of 325,388 shares. The stock had previously closed at GBX 4.50 ($0.06).
Verici Dx Stock Performance
The firm has a market capitalization of £10.02 million, a price-to-earnings ratio of -225.00 and a beta of 1.59. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The stock’s 50-day moving average is GBX 6.58 and its 200-day moving average is GBX 7.11.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Further Reading
- Five stocks we like better than Verici Dx
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Broadcom’s Targeted Upside Just Keeps Getting Better
- How to Use Stock Screeners to Find Stocks
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Stock Splits, Do They Really Impact Investors?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
